Connect Biopharma Holdings Ltd is trading 7.5% up today at $2.14. - The company announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating rademikibart, its next-generation anti-interleukin-4-receptor alpha (IL-4RĪ±) antibody. - This milestone marks a significant step towards advancing the biologic for acute exacerbations in patients with asthma and type 2 inflammation. - Broader U.S. indices are trading roughly flat, suggesting the rally is driven by this stock-specific development rather than market-wide trends.